Brain surgery and gene therapy aim to tame Parkinson's symptoms

NCT ID NCT07533591

Not yet recruiting Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new gene therapy for Parkinson's disease. Six participants will receive a virus-based treatment injected into a specific brain area during surgery. Afterward, they take a drug to control abnormal brain activity and improve movement. The main goal is to check safety, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STP-001 (gene therapy with AAV vector and clozapine)
What this could lead to: If it works, this could point toward a new way to control Parkinson's motor symptoms without long-term medication side effects.
What could go wrong: This is a very early, small trial (6 people) focused on safety, not proof of effectiveness. The approach is experimental and may not work or could cause side effects like brain inflammation or movement problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE (PD)

Contacts and locations

Locations

Second Affiliated Hospital, School of Medicine,Zhejiang University

Zhejiang, Province, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.